FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Related Tags >> Provenge   Prostate Cancer   Cancer Drugs   FDA
Syndicate content

Dendreon News

Most Popular Dendreon Story

Is Dendreon a likely takeover target?

The stock analysts like everything they've seen about Dendreon's new data on the prostate cancer vaccine Provenge. They like it so much, some think the biotech has made itself an appealing buyout... Read more...

Latest Headlines